PROGEN Biotechnik

Starting out in 1983 as pioneers in antibody manufacturing, PROGEN has since become a globally operating biotech company that serves the life science and pharma sectors. We believe that our research antibodies and test kits are more than commodities but enabling tools for the advancement of research and development in academia and industry alike. Our goal is to deliver innovative and reliable products that fuel biopharmaceutical and diagnostic progress along the complete value chain - from the lab to manufacturing and quality control. PROGEN is continuously expanding its selection of over 1.000 research antibodies in different formats to enable novel applications that facilitate and accelerate the workflow at the bench. Building on our core competence in immunochemistry, PROGEN's portfolio includes adeno-associated virus (AAV) gene therapy tools, phage display technology and libraries for the generation of novel recombinant antibodies as well as density gradient media for easy cell fractionation. We place great value on premium quality and are breaking new ground in product validation to meet the key demand of the research community for high quality, reliable immunochemicals. Based in Heidelberg, PROGEN has been a 100% subsidiary of R-Biopharm AG since 2012.